[Histological changes following scleral buckling operation for retinal detachment].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to W Paul.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
An oral formulation based on liposome encapsulated alginate-chitosan gel capsules was developed for insulin delivery for the treatment of diabetes. Liposome encapsulation helped to increase the encapsulation efficiency of insulin in alginate-chitosan capsules. This formulation delivers insulin in the neutral environment of the intestine, by-passing the acidic media in the stomach, with increased drug absorption and bioavailability. Oral administration of this formulation was found to reduce blood glucose levels when tested in diabetic rats.
Comparative pharmacological and toxicological studies were carried out on animals covering the preparation d,1-oxyphedrine (myophedrine), put out in the GDR, as against the drug 1-oxyphedrine. The activity of both drugs showed no material difference. Clinical trials demonstrated good tolerance of the drug both by healthy persons and patients with its intravenous administration twice a day in amounts of 1 mg, or by mouth--3 times a day in amounts of 8--16 mg. In outpatients with anginal pains after sustained myocardial infarction and also in institutionally treated patients with myocardial infarction the activity of d,1-oxyphedrine proved to be not inferior to that of 1-oxyphedrine.